cell. Therefore, highly metastatic cells often acquire alterations 1-1 Tsukiji 5-chome, Chuo-ku, Tokyo 104-0045, Japan in more genes than non-metastatic cells, and various genes are
differentially expressed between metastatic and non-metastatic It is now widely accepted that cancer is attributed to cells. Such cells selectively produce a metastatic tumor in a the accumulation of genetic alterations in cells. Thus, to distant organ; thus, cells in the metastatic tumor are considered understand the molecular mechanisms of cancer metastasis, to carry all the genetic alterations necessary to maintain it is indispensable to identify the genes whose alterations malignant phenotypes of cancer cells, including invasiveness accumulate during cancer progression as well as the genes and metastatic ability (Figure 1 ). whose expression is responsible for the acquisition of Two different molecular approaches have been taken to metastatic potential in cancer cells. Molecular analyses of identify such genes. One is the identification of genes whose cancer cells in various stages of progression have revealed alterations accumulate during cancer progression. The other that alterations in tumor suppressor genes and oncogenes is the identification of genes whose expression is responsible accumulate during tumor progression and correlate with for the acquisition of metastatic potential in cancer cells.
the clinical aggressiveness of cancer. Comparative analyses
During the two decades of molecular biological studies on of gene expression profiles between metastatic and nonhuman cancer, a number of genes have been identified as metastatic cells have revealed that various genes are being genetically or epigenetically altered, specifically in fardifferentially expressed in association with the metastatic advanced and/or highly metastatic cancer cells. On the bases potential of cancer cells. A number of genes have been also of those pieces of information, the process of invasion and identified as having functions in inducing or suppressing metastasis has been understood in association with genetic metastasis in experimental models. However, the association and/or epigenetic alterations of defined genes in cancer cells. between causative genetic alterations and resulting phenoIn this review, I will summarize the major developments typic alterations with respect to the metastatic potential of for the identification of genes involved in tumor progression cancer cells is not fully understood. Therefore, elucidation and metastasis in the past 20 years, and summarize the genes of genotype-phenotype correlation will be required to whose alterations occur specifically in advanced cancer cells further understand a complex process of metastasis. Here, and the genes whose expression is responsible for the acquisi-I review the progress on molecular studies of tumor tion of metastatic activity in cancer cells. progression and metastasis of the past 20 years and discuss the future direction in this field of science.
Presence of multiple genetic alterations in human cancer cells
Since cancer is attributed to genetic alterations accumulated Introduction in the cells, it is indispensable to identify genes whose Stepwise progression of human cancer has been clinically well alterations accumulate during tumor progression to understand recognized. Several types of pre-malignant lesions, such as the molecular mechanisms of metastasis. Over the past 2 dysplasia and hyperplasia, can be detected in diverse organs decades, a number of genes that are genetically altered in prior to the appearance of fully malignant invasive tumors.
human cancer cells have been identified. Identification of The pre-malignant lesions are caused either by genetic alteraseveral oncogenes in the early 1980s has opened the way to tions which induce monoclonal expansion of the cells, or by search for genetic alterations in human cancer cells and, up to environmental factors, such as viral infection, which induce now, nearly 100 oncogenes have been identified (1,2). Isolation polyclonal expansion of the cells. Subsequently, accumulation of tumor suppressor genes in the late 1980s and 1990s has of genetic alterations occur in one (or a few) of the prefurther accelerated the studies on genetic alterations in human malignant cells, and the cells convert into malignant ones of cancer cells and provided us with a large amount of valuable clonal origin and produce a primary tumor. However, at the information on understanding the underlying genetic alterations early stage of primary tumor expansion, the cells are not in human cancer cells. invasive and metastatic. Then, new clones with invasiveness
In particular, in the early period of studies on tumor and metastatic ability appear as a result of further accumulation suppressor genes, restriction fragment length polymorphism of genetic alterations in the cells. Thus, fully malignant cells (RFLP) analysis (3) was used extensively, and it has been are invasive and metastatic; however, only a restricted fraction shown by the RFLP studies that loss of heterozygosity (LOH) of the cells in a primary tumor are considered to be highly occurs frequently at multiple chromosomal loci in a variety of metastatic. Namely, cells in a primary tumor are phenotypically human cancers (4,5 metastases is significantly higher than that in primary tumors, was revealed by mutational analyses of those genes.
and support the concept of multistage carcinogenesis in association with accumulation of genetic alterations during Accumulation of genetic alterations during tumor tumor progression. In addition, several chromosomal loci progression showed LOH more frequently in metastases, suggesting that The presence of multiple genetic alterations in cancer cells some tumor suppressor genes are involved in acquisition of strongly indicated that those alterations accumulate in the cells metastatic potential in cancer cells. In particular, frequent in a stepwise manner during tumor progression. To prove LOH on chromosome 14q has been consistently observed in this assumption, comparative analyses of genetic alterations metastatic and advanced colorectal carcinomas among the between early and late stage tumors have been extensively studies of three different groups (18, 19, 23, 25) , suggesting that performed in various types of human cancers. The number of chromosome 14q harbors a metastasis suppressor gene for genetic alterations in late stage tumors were usually more than colorectal carcinoma. Chromosomes 18q and 22q are also those in early stage tumors in various types of cancers. The common targets of frequent LOH in both colorectal and lung frequencies of alterations in a set of the genes analyzed were cancers of aggressive phenotypes (21, 22, (26) (27) (28) . However, higher in late stage tumors than in early stage tumors, while target genes on these chromosome arms have not yet been those in another set of genes were high in both early and late identified. stage tumors. Based on the results of those studies, genetic models for tumor progression have been constructed in various Prognostic significance of oncogene and tumor suppressor types of human cancers in association with accumulation of gene alterations genetic alterations in cancer cells. Such a genetic model was first demonstrated on colorectal carcinoma, since tumors in
In the field of clinical oncology, it is very important to identify molecular markers for the evaluation of prognosis in cancer various stages of progression, from small adenomas to large metastatic carcinomas, can be relatively easily obtained for patients. Thus, association between oncogene alterations in cancer cells and prognosis of patients has been extensively analysis (12,14,17). Subsequently, similar genetic models have been constructed for various types of human cancers. Since investigated in various types of human cancers. For instance, amplification of the N-myc oncogene is now a valuable stepwise accumulations of genetic alterations during progression have been observed in several tumor types, in particular prognostic marker for patients with neuroblastoma (29, 30) , and amplification/overexpression of the c-erbB-2 oncogene is in tumors of epithelial origin, the concept of multistage carcinogenesis is now widely accepted as being a consequence also a marker for the aggressiveness of ovarian and breast cancers (31, 32) . In general, oncogene amplification occurs of multiple genetic alterations accumulated in cancer cells.
Then what are the genes responsible for the acquisition of late in tumor progression and correlates well with clinical aggressiveness of tumors (33, 34) . Point mutations of the ras metastatic potential in cancer cells? Based on the concept oncogenes, in particular of the K-ras gene, occur in a variety allelotypes are different among tumors of different origin, supporting the idea that genes for metastasis are also different of human cancers, such as pancreatic cancer, colorectal cancer, lung adenocarcinoma and thyroid carcinoma. The prognostic among tumors of different origin. However, it is still unknown which genes are responsible for the acquisition of metastatic significance of ras mutation has been documented in lung adenocarcinoma (35) .
potential in any types of cancers. Thus, it is now very important to identify genes which are affected by LOH specifically in In contrast, the prognostic significance of tumor suppressor gene inactivation is still unclear or controversial in several metastatic tumors. Another important finding coming from molecular analyses types of cancers, although that of LOH on several chromosomes has been documented in a variety of cancers. This could be of human cancers is the discovery of multiple pathways for carcinogenesis in tumors of the same histological type. In partly due to the technical difficulties in detecting various types of tumor suppressor gene alterations, including point colorectal cancer, the microsatellite mutator phenotype (MMP) was discovered by the application of the arbitrarily primed mutations, intragenic insertions/deletions and homozygous whole-gene deletions, by a simple method. Methylational PCR DNA fingerprinting method to the analysis of somatic genetic alterations in tumors (41, 42 ). This phenotype is now inactivation should be also considered as a mechanism of tumor suppressor gene inactivation, as in the case of the p16 known to be a consequence of somatic or germ-line inactivation in DNA mismatch repair genes (12,43). Hereditary nongene (36) . Alternatively, it is also possible that most tumor suppressor genes are involved in the genesis rather than the polyposis colorectal cancer (HNPCC) is caused by hereditary mutations of a mismatch repair gene (12). Tumors with MMP progression of cancer, since those are also genes responsible for hereditary tumors (8,9). We should also consider that the exhibit a low frequency of mutations in the K-ras, APC and p53 genes, but a high frequency of mutations in the genes biological significance of tumor suppressor gene alterations is different among types of mutations and among types of cancers.
with simple repeated sequences, such as the TGF-β receptor and BAX genes (44, 45) . These results indicate the existence In particular, the p53 gene has multiple functions and several mutant forms should still keep some normal functions, so it is of at least two distinct pathways for colorectal carcinogenesis. These two pathways should also exist in other types of likely that the phenotypes of cancer cells are different if the types of mutations are different. Therefore, it is now very HNPCC-associated cancers, such as cancer of the endometrium, although the prevalence of endometrial cancer with MMP important to elucidate more critically the association of cancer phenotypes with cancer genotypes for the analysis of tumor would not be so high as that of colorectal cancer with MMP.
In cancers not associated with HNPCC, it is still unclear suppressor genes.
whether there are multiple pathways for carcinogenesis. If there are, the phenotype (biological behavior) of cancer cells Tumor type specificity of genetic alterations should be different even among tumors derived from the same origin of precursor cells, because of the difference in a set of Molecular genetic analyses of various types of human cancers have also revealed that there are two groups of genes involved genes altered in cancer cells. Frequencies of p53 mutations vary considerably among tumors of different histological types in human carcinogenesis. One is a group of genes which are genetically altered commonly in diverse tumor types, and the (46, 47) and, in tumors without p53 mutations, alterations in genes upstream or downstream of the p53 gene cannot be other is a group of genes which are altered specifically in particular tumor types (1,8) . Examples of the former group always detected. Thus, it is possible that multiple pathways for carcinogenesis exist in those tumors. Accordingly, it has are p53, RB and p16, and those of the latter are VHL, RET and various genes translocated in leukemia cells. Mutations of been suggested that there are several different sets of genes involved in metastasis even in the same histological types the p53 gene have been found most widely in a variety of tumors (37, 38) , whereas RB and p16 inactivation is somewhat of cancers. limited to a more restricted group of tumors. Interestingly, the RB and p16 genes are preferentially inactivated in small-cell Tumor cell heterogeneity with respect to metastatic lung carcinoma (SCLC) and non-SCLC, respectively, although potential of cancer cells both genes are involved in the same signaling pathway for the regulation of the G 1 /S transition of the cell cycle (39, 40) .
Another approach in defining a set of genes involved in metastasis is a comparative study of cancer cells with metastatic Mutations of the VHL and RET genes have been detected exclusively in renal cell cancer and thyroid cancer, respectively. potential and of those without metastatic potential. It was nearly 30 years ago that Fidler first demonstrated the heterogeneity of What is the implication of tumor type specificity for genetic alterations? It implies that a set of responsible genes for mouse melanoma cells with respect to metastatic potential (48). In other words, he successively selected sub-lines with carcinogenesis is different among cells of different histological types. Some genes are commonly involved in the malignant different metastatic potential from a mouse melanoma cell line. His study clearly indicated that a primary tumor often transformation of diverse cell types, whereas some other genes are involved in that of particular cell types.
contains sub-populations of metastatic and non-metastatic cancer cells. Since then, several similar animal models have If a set of genes altered in cancer cells is different among tumors of different histological types, it is highly possible that been developed, and the concept of tumor cell heterogeneity with respect to the metastatic potential has now been well critical genetic alterations for the acquisition of metastatic potential are also different among cancers of different origin.
established and widely accepted (49). This concept has made the studies on metastasis genes more difficult, because highly At present, we do not know whether genes responsible for metastatic potential are common in all different histological metastatic cells are present as a small (or large) population in a primary tumor, based on this concept. If so, we have to find types of tumors or unique and peculiar to particular tumor types. However, LOH studies on various types of advanced some specific marker to select the cells with high metastatic potential in the primary tumor. Such a marker should be a and metastatic cancers have indicated that the profiles of specific genetic alteration, but one which is accumulated in cancer cells during tumor progression. For this reason, several transfection studies of DNA from highly metastatic human tumors have been performed (50, 51) ; however, to date, no genes inducing or suppressing metastasis have been identified by this method.
Differential gene expression in association with metastatic potential of cancer cells
However, isolation of high-and low-metastatic subclones from levels during the last 2 decades. The cDNA differential or subtractive hybridization method was often used in the 1980s NIH 3T3 cells (60) . However, clinically, ras mutation occurs and the mRNA differential display method (52) Tumor suppressor genes constitute key points in many considered to have critical functions in regulating metastatic complex cellular pathways that regulate proliferation, activity in human cancer cells. However, no genetic alterations differentiation, apoptosis and response to genetic damage of those genes have been found in human cancer cells, and (8,9). To date, there has been no evidence that any of the expression profiles of those genes in human cancer cells do known tumor suppressor genes are involved specifically in the not always correlate with the metastatic potential of the cells.
stage of invasion and metastasis (Figure 2 ). However, some Therefore, it is still unclear whether the expression profiles of tumor suppressor genes may have a function partly in the those genes are clinically valuable for the prediction of stage of tumor progression. For instance, loss of E-cadherin metastatic potential in cancer patients. function in tumors results in the rapid progression of relatively benign adenomas to invasive, metastatic carcinomas. Germline Association of genetic alterations with metastatic phenotype mutation of the E-cadherin gene predisposes to diffuse, poorly of cancer cells differentiated gastric cancer, and its downregulation in sporadic tumors is associated with poor clinical prognosis (62) . Recent To understand how cancer cells acquire metastatic potentials, it is necessary to clarify the causative genetic alterations studies have indicated that angiogenesis may be regulated, in part, by p53 tumor suppressor gene function (63-65). As for metastatic transformation of normal cells and resulting epigenetic alterations unique to cancer cells with metastatic mentioned before, there are several specific chromosomal regions which are preferentially deleted in advanced and ability (60, 61) . We now know that a number of oncogenes and tumor suppressor genes are genetically altered in cancer metastatic cancers. Thus, it is highly possible that there are several unknown tumor suppressor genes involved specifically cells and that those alterations accumulate during tumor progression. Thus, it goes without saying that alterations of in tumor progression and metastasis. Very recently, a cancer model in which dominantly acting those genes are causative events for multistage carcinogenesis, although we still do not know which genes are responsible oncoproteins are somatically regulated in vivo has been developed, and it was shown using such a model that melanoma for the acquisition of invasiveness and metastatic potential in cancer cells (Figure 2 ). In the meantime, the number of genesis and maintenance are strictly dependent on expression of an activated H-ras gene in a doxycycline-inducible mutated candidate genes whose expression could possibly change the metastatic potential of human cancer cells has been increasing.
H-ras mouse melanoma model null for the p16 gene (66) . This kind of mouse model system could be suitable for the Thus, by analyzing genotype-phenotype correlation with respect to metastatic potential, it should be possible to identify functional analysis of various metastasis-related genes in vivo. On the other hand, different susceptibility to malignant transgenetic alterations responsible for metastasis.
Suitable assay systems are required for the functional formation by oncogenes has been shown between rodent cells and human cells. According to the paper by Hahn et al. (67) , analysis of gene products with respect to metastasis. NIH 3T3 cells have often been used as recipients of transfection with one important difference between rodent and human cells comes from their telomere biology. Murine somatic cells various oncogenes. Interestingly, the metastatic phenotype was accomplished by transfection of mutated ras oncogenes into express telomerase activity and have much longer telomeres than their normal human counterparts, which lack telomerase respect to metastatic potentials. However, once we obtain molecular markers for prediction of metastatic potential of activity. It was shown that the ectopic expression of the telomerase catalytic subunit (hTERT) gene in combination with cancer cells, several methods can be applied in clinics (72). One of the most valuable and attractive technologies applicable two oncogenes resulted in direct tumorigenic conversion of normal human epithelial and fibroblast cells. This method can in clinics will be the establishment of a method to comprehensively analyze the whole genome in a single cell (73). be also applied for biological analysis of metastasis-associated human genes. However, genetic activation of the hTERT Then, in the near future, it will be possible to identify all types of genetic alterations and to see the expression profile of the gene has not been identified in human cancer to date; thus, elucidation of the mechanism for hTERT activation is necessary whole 100 000 genes in each single cell in a tumor. The information obtained by those analyses will definitely conto understand the process of multistage carcinogenesis in human cells.
tribute to the creation of new principles for prevention, diagnosis and therapy of metastasis.
Future directions
Acknowledgements The most devastating aspect of cancer is the emergence of aggressiveness of cancer at bedside in future.
